These results offer a new insight into the biology and treatment of pediatric T-ALL by providing a new targeted therapy option with the use of LCK inhibitors, which could be easily rendered into clinical practice in an attempt to overcome GC resistance and improve the outcome of poor-responder T-ALL pediatric patients [99]. The gene discussed is LCK; the disease is acute lymphoblastic leukemia.